Evidence map›Paper›PMID 37143335›Full record

ArticlePsychiatric services (Washington, D.C.)2023

Transitions in Prescription Benzodiazepine Use and Misuse and in Substance Use Disorder Symptoms Through Age 50.

Sean Esteban McCabe, John E Schulenberg, Timothy E Wilens, Ty S Schepis, Vita V McCabe, Philip Veliz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatric services (Washington, D.C.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sean Esteban McCabeCenter for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing, Ann Arbor (all authors); Institute for Social Research (S. E. McCabe, Schulenberg, Veliz) and Department of Psychiatry (V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
John E SchulenbergCenter for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing, Ann Arbor (all authors); Institute for Social Research (S. E. McCabe, Schulenberg, Veliz) and Department of Psychiatry (V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
Timothy E WilensCenter for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing, Ann Arbor (all authors); Institute for Social Research (S. E. McCabe, Schulenberg, Veliz) and Department of Psychiatry (V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
Ty S SchepisCenter for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing, Ann Arbor (all authors); Institute for Social Research (S. E. McCabe, Schulenberg, Veliz) and Department of Psychiatry (V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
Vita V McCabeCenter for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing, Ann Arbor (all authors); Institute for Social Research (S. E. McCabe, Schulenberg, Veliz) and Department of Psychiatry (V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
Philip VelizCenter for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing, Ann Arbor (all authors); Institute for Social Research (S. E. McCabe, Schulenberg, Veliz) and Department of Psychiatry (V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).

Funding

Monitoring the Future: Drug Use & Lifestyles of American Youth (Supp1: Nicotine Pouch and E-cigarette Use Among US Adolescents: National Estimates of Brand Use and Flavor Preferences)R01DA001411 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Richard A Miech · 1985 to 2026
$144.9M
Monitoring the Future: A Cohort-Sequential Panel Study of Drug Use, Ages 19-65 - Diversity Supplement (Solberg)R01DA016575 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Megan E. Patrick · 2003 to 2026
$44.6M
Trajectories of Prescription Nonmedical Drug MisuseR01DA031160 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SEAN ESTEBAN MCCABE · 2011 to 2026
$3.7M
Longitudinal Changes in Recovery from Drug Use Disorders: A National StudyR01DA036541 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCCABE, SEAN ESTEBAN · 2015 to 2017
$647k
Nonmedical prescription drug misuse among US older adults: subtypes,motives, and diversion sourcesR01DA042146 · NIDA · TEXAS STATE UNIVERSITY · PI SCHEPIS, TY STEPHEN · 2017 to 2021
$548k
NIDA NIH HHS R01 DA001411NIDA NIH HHS R01 DA016575NIDA NIH HHS R01 DA031160NIDA NIH HHS R01 DA036541NIDA NIH HHS R01 DA042146
6 · The paper itself

Abstract

objectivePrescription benzodiazepines are among the most commonly used and misused controlled medications. The authors aimed to examine transitions from medical use of prescription benzodiazepines to prescription benzodiazepine misuse, prescription opioid misuse, and substance use disorder symptoms during adulthood.

methodsEleven national cohorts of U.S. 12th graders (N=26,575) were followed up from ages 18 (1976-1986) to 50 (2008-2018). Prescription benzodiazepine misuse, prescription opioid misuse, and substance use disorder symptoms were examined with prevalence estimates and multivariable logistic regression.

resultsBy age 35, 70.9% of respondents had not used or misused prescription benzodiazepines, 11.3% reported medical use only, 9.8% indicated both medical use and misuse, and 14.1% reported misuse only. In analyses adjusted for demographic and other characteristics, adults reporting only medical use of prescription benzodiazepines by age 35 had higher odds of later prescription benzodiazepine misuse (adjusted OR [AOR]=2.17, 95% CI=1.72-2.75) and prescription opioid misuse (AOR=1.40, 95% CI=1.05-1.86) than respondents ages 35-50 who never used prescription benzodiazepines. More frequent medical use of prescription benzodiazepines by age 35 was associated with increased risk for substance use disorder symptoms at ages 40-50. Any history of prescription benzodiazepine misuse by age 35 was associated with higher odds of later prescription benzodiazepine misuse, prescription opioid misuse, and substance use disorder symptoms, compared with no misuse.

conclusionsPrescription benzodiazepine use or misuse may signal later prescription drug misuse or substance use disorders. Medical use of prescription benzodiazepines by age 35 requires monitoring for prescription drug misuse, and any prescription benzodiazepine misuse warrants an assessment for substance use disorder.

Indexed as

Opioid-Related DisordersPrescription Drug MisuseAdultAnalgesics, OpioidBenzodiazepinesHumansLogistic ModelsMiddle AgedPrescriptionsAnalgesics, OpioidBenzodiazepinesAddictionAlcohol and drug abuseBenzodiazepinesDrug abuseEpidemiologyOpioid

Identifiers

PMID37143335
PMCPMC10867819

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.